Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA.

Selby, Nicholas M; Blankestijn, Peter J; Boor, Peter; Combe, Christian; Eckardt, Kai-Uwe; Eikefjord, Eli; Garcia-Fernandez, Nuria; Golay, Xavier; Gordon, Isky; Grenier, Nicolas; Hockings, Paul D; Jensen, Jens D; Joles, Jaap A; Kalra, Philip A; Krämer, Bernhard K; Mark, Patrick B; Mendichovszky, Iosif A; Nikolic, Olivera; Odudu, Aghogho; Ong, Albert C M; ... (2018). Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. Nephrology, dialysis, transplantation, 33(suppl_2), ii4-ii14. Oxford University Press 10.1093/ndt/gfy152

[img]
Preview
Text
CMI-3-173.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (394kB) | Preview

Functional renal magnetic resonance imaging (MRI) has seen a number of recent advances, and techniques are now available that can generate quantitative imaging biomarkers with the potential to improve the management of kidney disease. Such biomarkers are sensitive to changes in renal blood flow, tissue perfusion, oxygenation and microstructure (including inflammation and fibrosis), processes that are important in a range of renal diseases including chronic kidney disease. However, several challenges remain to move these techniques towards clinical adoption, from technical validation through biological and clinical validation, to demonstration of cost-effectiveness and regulatory qualification. To address these challenges, the European Cooperation in Science and Technology Action PARENCHIMA was initiated in early 2017. PARENCHIMA is a multidisciplinary pan-European network with an overarching aim of eliminating the main barriers to the broader evaluation, commercial exploitation and clinical use of renal MRI biomarkers. This position paper lays out PARENCHIMA's vision on key clinical questions that MRI must address to become more widely used in patients with kidney disease, first within research settings and ultimately in clinical practice. We then present a series of practical recommendations to accelerate the study and translation of these techniques.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Institute of Diagnostic, Interventional and Paediatric Radiology

UniBE Contributor:

Thöny, Harriet C.

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0931-0509

Publisher:

Oxford University Press

Language:

English

Submitter:

Isabelle Ursula Saurer

Date Deposited:

07 Mar 2019 15:19

Last Modified:

12 Nov 2019 07:42

Publisher DOI:

10.1093/ndt/gfy152

PubMed ID:

30137584

BORIS DOI:

10.7892/boris.125581

URI:

https://boris.unibe.ch/id/eprint/125581

Actions (login required)

Edit item Edit item
Provide Feedback